PL374431A1 - Kompozycje i sposoby dla działania terapeutycznego - Google Patents

Kompozycje i sposoby dla działania terapeutycznego

Info

Publication number
PL374431A1
PL374431A1 PL03374431A PL37443103A PL374431A1 PL 374431 A1 PL374431 A1 PL 374431A1 PL 03374431 A PL03374431 A PL 03374431A PL 37443103 A PL37443103 A PL 37443103A PL 374431 A1 PL374431 A1 PL 374431A1
Authority
PL
Poland
Prior art keywords
compositions
methods
therapeutic treatment
therapeutic
treatment
Prior art date
Application number
PL03374431A
Other languages
English (en)
Inventor
Janette Lazarovits
Abraham Nimrod
Mar-Chaim Hagit Hoch
Avigdor Levanon
Original Assignee
Savient Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals, Inc. filed Critical Savient Pharmaceuticals, Inc.
Publication of PL374431A1 publication Critical patent/PL374431A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061Blood cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL03374431A 2002-07-01 2003-06-30 Kompozycje i sposoby dla działania terapeutycznego PL374431A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18902502A 2002-07-01 2002-07-01

Publications (1)

Publication Number Publication Date
PL374431A1 true PL374431A1 (pl) 2005-10-17

Family

ID=29999592

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03374431A PL374431A1 (pl) 2002-07-01 2003-06-30 Kompozycje i sposoby dla działania terapeutycznego

Country Status (12)

Country Link
EP (1) EP1551452A4 (pl)
JP (1) JP2005534679A (pl)
KR (1) KR20050059001A (pl)
CN (1) CN1678348A (pl)
AU (1) AU2003279657A1 (pl)
BR (1) BR0312484A (pl)
CA (1) CA2491427A1 (pl)
IL (1) IL166062A0 (pl)
MX (1) MXPA05000271A (pl)
PL (1) PL374431A1 (pl)
RU (1) RU2005101622A (pl)
WO (1) WO2004002528A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
JP2007530603A (ja) * 2004-03-30 2007-11-01 デン コンゲリク ベテリネル−オク ランドボホイスコレ プロテアーゼ阻害物質の遮断又は検出による癌治療及び癌治療効能予測の改善
PL1737428T3 (pl) * 2004-03-31 2018-03-30 University Of Utah Research Foundation Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych
KR20080056167A (ko) 2005-09-26 2008-06-20 메다렉스, 인코포레이티드 씨디70에 대한 인간 모노크로날 항체
RU2366434C1 (ru) * 2007-12-07 2009-09-10 Институт неорганической химии им. А.В. Николаева Сибирского отделения Российской Академии наук Гексаядерные кластерные комплексы рения на основе радиоактивных изотопов, обладающие противоопухолевыми свойствами
CA2747154C (en) * 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
CN102116554A (zh) 2010-01-04 2011-07-06 Lg电子株式会社 电冰箱
CN106659784B (zh) 2014-07-08 2022-03-29 桑福德伯纳姆医学研究所 Psgl-1调控剂及其用途
RU2766000C2 (ru) 2016-01-08 2022-02-07 АльтруБио Инк. Четырехвалентные антитела к psgl-1 и их применения

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05244987A (ja) * 1992-02-28 1993-09-24 Unitika Ltd 抗硫酸化チロシン抗体,その製造方法及び抗硫酸化チロシンモノクローナル抗体を産生するハイブリドーマ
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
EP1098665B9 (en) * 1998-07-13 2003-08-13 The Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
AU774419C (en) * 1998-10-30 2005-03-03 Genetics Institute, Llc Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists
EP1284751A1 (en) * 2000-05-11 2003-02-26 National Tsing Hua University Compositions and methods for induction of active autoimmunity
EA005931B1 (ru) * 2000-05-15 2005-08-25 Фармация Италия С.П.А. Ингибиторы ароматазы и моноклональные антитела против her2 как противоопухолевые агенты
HUP0700079A2 (en) * 2000-12-29 2007-05-02 Savient Pharmaceuticals Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CA2433227A1 (en) * 2000-12-29 2002-08-01 Bio-Technology General, Inc. Specific human antibodies for selective cancer therapy

Also Published As

Publication number Publication date
EP1551452A4 (en) 2006-08-30
WO2004002528A1 (en) 2004-01-08
KR20050059001A (ko) 2005-06-17
RU2005101622A (ru) 2006-01-27
CN1678348A (zh) 2005-10-05
IL166062A0 (en) 2006-01-15
BR0312484A (pt) 2008-01-08
AU2003279657A1 (en) 2004-01-19
EP1551452A1 (en) 2005-07-13
MXPA05000271A (es) 2005-03-31
CA2491427A1 (en) 2004-01-08
WO2004002528A9 (en) 2004-11-18
JP2005534679A (ja) 2005-11-17

Similar Documents

Publication Publication Date Title
GB0201850D0 (en) Therapeutic treatment
GB0216321D0 (en) Therapeutic treatment
IL172194A0 (en) Methods and compositions for treating amyloid-related diseases
GB0316912D0 (en) Therapeutic treatment
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
GB0320806D0 (en) Therapeutic treatment
AU2003287443A8 (en) Compositions and methods for pain reduction
SI1545256T1 (sl) Naprava za terapevtsko zdravljenje
GB0223367D0 (en) Therapeutic treatment
GB0303609D0 (en) Novel therapeutic method and compositions
AU2003232044A8 (en) Composition and method for dermatological treatment
GB0223854D0 (en) Therapeutic treatment
IL166062A0 (en) Compositions and methods for therapeutic treatment
GB0210464D0 (en) Therapeutic treatment
EP1569928A4 (en) THERAPEUTIC COMPOUNDS AND METHOD
AU2003275433A8 (en) Compositions and methods for treating pain
GB0307863D0 (en) Therapeutic treatment
AU2003291730A8 (en) Methods and compositions for treating neurodegenerative diseases
GB0327050D0 (en) Therapeutic methods compositions and uses
EP1583543A4 (en) METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA
GB0313772D0 (en) Therapeutic treatment
GB0303600D0 (en) Novel therapeutic method and compositions
GB0221712D0 (en) Methods of treatment
GB0205826D0 (en) Therapeutic compositions and methods
IL163878A0 (en) Compositions and methods for treating mdma-inducedtoxicity

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)